Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

This study has been completed.
Information provided by:
Alexza Pharmaceuticals, Inc. Identifier:
First received: November 7, 2008
Last updated: May 4, 2009
Last verified: May 2009
The objective of this trial is to assess the pulmonary safety of 2 inhaled doses of Staccato Loxapine within a day.

Condition Intervention Phase
Drug: Placebo -- Active
Drug: Active -- Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pulmonary Safety of Repeat Doses of Staccato® Loxapine for Inhalation in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by Alexza Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Change in FEV1 from baseline by spirometry [ Time Frame: at each post-treatment time point (15 min to 32 hr) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change in FVC from baseline by spirometry [ Time Frame: Post-treatment time points ] [ Designated as safety issue: Yes ]
  • Treatment emergent adverse events [ Time Frame: Post-treatment time points ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: November 2008
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Placebo -- Active
Drug: Placebo -- Active
Placebo followed by Active (Staccato Loxapine, 10 mg x 2)
Experimental: 2
Active -- Placebo
Drug: Active -- Placebo
Active (Staccato Loxapine, 10 mg x 2) followed by Placebo

Detailed Description:
The planned study is a multiple dose, double-blind, placebo-controlled, randomized, 2-sequence, 2-period crossover study investigating pulmonary safety in healthy volunteers.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • nonsmoker subjects in good general health with normal spirometry at screening AND baseline

Exclusion Criteria:

  • history of asthma, COPD, or any other acute or chronic pulmonary disease or bronchodilator use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00789360

United States, Massachusetts
Northeast Medical Research
North Dartmouth, Massachusetts, United States, 02747
Sponsors and Collaborators
Alexza Pharmaceuticals, Inc.
Principal Investigator: David S. Miller, MD Northeast Medical Research, North Dartmouth, MA
  More Information

Responsible Party: Robert Fishman, MD., Vice President, Clinical Development, Alexza Pharmaceuticals, Inc. Identifier: NCT00789360     History of Changes
Other Study ID Numbers: AMDC-004-104  12 September 2008 
Study First Received: November 7, 2008
Last Updated: May 4, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Alexza Pharmaceuticals, Inc.:
Healthy volunteers

Additional relevant MeSH terms:
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on December 09, 2016